Anticoagulant agents useful in treatment of thrombosis

• US 20070003553A1
• Filed: 08/11/2005
• Published: 01/04/2007
• Est. Priority Date: 01/17/1996
• Status: Abandoned Application

• Current Assignee: University of Vermont & State Agricultural College
• Original Assignee: Smithkline Beecham Corporation and The University of Vermont and State Agricultural College
• Inventors: Padlan, Eduardo, Blackburn, Michael, Nichols, Andrew, Patel, Arunbhai, Church, William, Feuerstein, Giora, Gross, Mitchell, Sylvester, Daniel
• Application Number:
  US11/201,592
• Publication Number:
  US 20070003553A1
• Time in Patent Office: Days
• US Class Current: 424/146.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: C07K 16/36 against blood coagulation factors
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Claims

1. A method for inhibiting thrombosis in an animal comprising administering an effective dose of an anti-coagulation factor IX/IXa monoclonal antibody having self-limiting neutralizing activity.

2. The method of claim 1 further comprising administering acetylsalicylic acid in combination with the anti-coagulation factor IX/IXa monoclonal antibody.

6. The method of claim 1 or 2 wherein the anti-coagulation factor IX/IXa monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.

7. The method of claim 1 or 2 wherein the anti-coagulation factor IX/IXa monoclonal antibody has the identifying characteristics of SB 249417.

10. The method of claim 1 or 2 wherein the thrombosis is associated with myocardial infarction, unstable angina, atrial fibrillation, stroke, renal damage, pulmonary embolism, deep vein thrombosis, percutaneous translumenal coronary angioplasty, disseminated intravascular coagulation, sepsis, artificial organs, shunts or prostheses.

39. The method of claim 10 wherein the thrombosis is associated with stroke.

40. The method of claim 10 wherein the thrombosis is associated with sepsis.

41. The method of claim 1 wherein the anti-coagulation Factor IX/IXa monoclonal antibody binds with an epitope of the Factor IXgla domain.

42. The method of claim 41 wherein the epitope is located within residues 3-11 of the Factor IXgla domain.

43. The method of claim 42 wherein the antibody has a binding affinity of at least 4 nM.

3-5. -5. (canceled)

8-9. -9. (canceled)

11-38. -38. (canceled)